Cited by 352Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 185 of the 187 references it cites were found in a registry or an index.

Moving towards personalized treatments of immune-related adverse events

Esfahani, Khashayar, Elkrief, Arielle, Calabrese, Cassandra, Lapointe, Réjean, Hudson, Marie, Routy, Bertrand, Miller, Wilson H., Calabrese, Leonard·2020·Nature Reviews Clinical Oncology

DOI 10.1038/s41571-020-0352-8

Open this paper in CoChat — free account

Abstract

The enhancement of immune responses upon treatment with immune checkpoint inhibitors can have the desired outcome of reinvigorating antitumour immune surveillance, but often at the expense of immune-related adverse events (irAEs). This novel disease entity often prompts comparisons with, and extrapolation of treatment approaches from, primary autoimmune disorders. Accordingly, current treatment guidelines for irAEs make generic recommendations adapted from the literature describing primary autoimmune diseases, without taking into consideration the substantial disparity of the immunohistopathological findings within each organ affected by an irAE. The treatment modalities themselves are complex and have many potential drawbacks, such as serious and rarely fatal infections, drug toxicities overlapping with irAEs and the risk of compromising cancer immune surveillance. Herein, we provide an overview of key cellular and soluble immunological factors mediating irAEs and propose a model integrating this knowledge with the immunohistopathological findings of the affected organs for a personalized decision-making process for each patient.

Integrity signals

Registry

Crossref · 10.1038/s41571-020-0352-8

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Self-citation
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature reviews. Immunology · doi:10.1038/nri1604 · Cited by 3,631
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
Self-citation
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237

Show all 187 references

Sorted by citations

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
Routy, B., Lenehan, J. G., Miller, W. H., Jamal, R., Messaoudene, M., Daisley, B. A., Hes, C., Al, K. F., Martinez-Gili, L., Punčochář, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02453-x · Cited by 526
Self-citation
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 495
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 403
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
Hailemichael, Y., Johnson, D. H., Abdel‐Wahab, N., Foo, W. C., Bentebibel, S.-E., Daher, M., Haymaker, C., Wani, K., Saberian, C., Ogata, D., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.004 · Cited by 372
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319
Immune mechanisms of toxicity from checkpoint inhibitors
Wang, S. J., Dougan, S. K., & Dougan, M. L. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.002 · Cited by 313
Advancing to the era of cancer immunotherapy
Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · 癌症：英文版 · doi:10.1002/cac2.12178 · Cited by 221
Second Near‐Infrared Light‐Activatable Polymeric Nanoantagonist for Photothermal Immunometabolic Cancer Therapy
Xu, C., Jiang, Y., Huang, J., Huang, J., & Pu, K. (2021) · Advanced Materials · doi:10.1002/adma.202101410 · Cited by 158
Corticosteroids and Cancer Immunotherapy
Goodman, R. S., Johnson, D. B., & Balko, J. M. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3181 · Cited by 168
Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy
Huppert, L. A., Green, M. D., Kim, L., Chow, C., Leyfman, Y., DAUD, A. I., & Lee, J. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00742-4 · Cited by 150
Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis
Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 135
Harnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19
Robinson, P. C., Liew, D. F. L., Liew, J. W., Monaco, C. G., Richards, D. B., Shivakumar, S., Tanner, H. L., & Feldmann, M. (2020) · Med · doi:10.1016/j.medj.2020.11.005 · Cited by 121
The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer
Singh, S., Numan, A., Maddiboyina, B., Arora, S., Riadi, Y., Md, S., Alhakamy, N. A., & Kesharwani, P. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.011 · Cited by 121
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy
Dimitriou, F., Hogan, S. A., Menzies, A. M., Dummer, R., & Long, G. V. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.031 · Cited by 129
Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
Verheijden, R. J., van Eijs, M. J. M., May, A. M., van Wijk, F., & Suijkerbuijk, K. P. M. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00380-1 · Cited by 128
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 120
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
Tay, S. H., Toh, M. M. X., Thian, Y. L., Vellayappan, B. A., Fairhurst, A., Chan, Y. H., Aminkeng, F., Bharwani, L. D., Huang, Y., Mak, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807050 · Cited by 122
Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies
Zahnreich, S., & Schmidberger, H. (2021) · Cancers · doi:10.3390/cancers13112607 · Cited by 132
Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
Jing, Y., Chen, X., Li, K., Liu, Y., Zhang, Z., Chen, Y., Liu, Y., Wang, Y., Lin, S. H., Diao, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003779 · Cited by 120
Faecalibacterium prausnitzii Abrogates Intestinal Toxicity and Promotes Tumor Immunity to Increase the Efficacy of Dual CTLA4 and PD-1 Checkpoint Blockade
Gao, Y., Xu, P., Sun, D., Jiang, Y., Lin, X.-L., Han, T., Yu, J., Sheng, C., Chen, H., Hong, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0605 · Cited by 116
Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management
Fleming, B., Edison, P., & Kenny, L. M. (2023) · BMJ · doi:10.1136/bmj-2022-071726 · Cited by 128
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy
Anscher, M. S., Arora, S., Weinstock, C., Amatya, A., Bandaru, P., Tang, C. Z., Girvin, A. T., Fiero, M. H., Tang, S., Lubitz, R., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.6439 · Cited by 113
Germline variants associated with toxicity to immune checkpoint blockade
Groha, S., Alaiwi, S. A., Xu, W. V., Naranbhai, V., Nassar, A. H., Bakouny, Z., Zarif, T. E., Saliby, R. M., Wan, G., Rajeh, A. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02094-6 · Cited by 121
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
Fa’ak, F., Buni, M., Falohun, A., Lu, H., Song, J., Johnson, D. H., Zobniw, C. M., Trinh, V. A., Awiwi, M. O., Tahon, N. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006814 · Cited by 117
Beneficial autoimmunity improves cancer prognosis
Zitvogel, L., Perreault, C., Finn, O. J., & Kroemer, G. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00508-x · Cited by 108
European recommendations for management of immune checkpoint inhibitors‐derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement
Apalla, Z., Nikolaou, V. A., Fattore, D., Fabbrocini, G., Freites‐Martínez, A., Sollena, P., Lacouture, M. E., Kraehenbuehl, L., Stratigos, A., Peris, K., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17855 · Cited by 108
Augmenting Immunogenic Cell Death and Alleviating Myeloid‐Derived Suppressor Cells by Sono‐Activatable Semiconducting Polymer Nanopartners for Immunotherapy
Ding, M., Zhang, Y., Yu, N., Zhou, J., Zhu, L., Wang, X., & Li, J. (2023) · Advanced Materials · doi:10.1002/adma.202302508 · Cited by 108
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
Frega, G., Wu, Q., Le Naour, J., Vacchelli, E., Galluzzi, L., Kroemer, G., & Kepp, O. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1796002 · Cited by 108
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab035 · Cited by 103
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
McKay, R. R., McGregor, B. A., Xie, W., Braun, D. A., Wei, X. X., Kyriakopoulos, C. E., Zakharia, Y., Maughan, B. L., Rose, T. L., Stadler, W. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02295 · Cited by 103
Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
Cortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 100
Strategies for improving the management of immune-related adverse events
Naing, A., Hajjar, J., Gulley, J. L., Atkins, M. B., Ciliberto, G., Meric‐Bernstam, F., & Hwu, P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001754 · Cited by 99
Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis
Franken, A., Mol, P. V., Vanmassenhove, S., Donders, E., Schepers, R., Brussel, T. V., Dooms, C., Yserbyt, J., Crem, N. D., Testelmans, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005323 · Cited by 101
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury
Zhang, Z., Zhou, J., Verma, V., Liu, X., Wu, M., Yu, J., & Chen, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774807 · Cited by 97
Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Ramos‐Casals, M., & Sisó‐Almirall, A. (2024) · Annals of Internal Medicine · doi:10.7326/aitc202402200 · Cited by 99
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity
Farina, A., Birzu, C., Elsensohn, M., Pïcca, A., Muñiz‐Castrillo, S., Vogrig, A., Villagrán‐García, M., Ciano-Petersen, N. L., Massacesi, L., Hervier, B., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad169 · Cited by 93
Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations
Casagrande, S., Sopetto, G. B., Bertalot, G., Bortolotti, R., Racanelli, V., Caffo, O., Giometto, B., Berti, A., & Veccia, A. (2024) · Cancers · doi:10.3390/cancers16071440 · Cited by 100
Current and future immunotherapy for breast cancer
Heater, N. K., Warrior, S., & Lu, J. M. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01649-z · Cited by 104
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
Maulana, T. I., Kromidas, E., Wallstabe, L., Cipriano, M., Alb, M., Zaupa, C., Hudecek, M., Fogal, B., & Loskill, P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.015 · Cited by 86
Biomimetic Nanocarriers Guide Extracellular ATP Homeostasis to Remodel Energy Metabolism for Activating Innate and Adaptive Immunity System
Wu, L., Xie, W., Li, Y., Ni, Q., Timashev, P. S., Lyu, M., Xia, L., Zhang, Y., Liu, L., Yuan, Y., et al. (2022) · Advanced Science · doi:10.1002/advs.202105376 · Cited by 87
Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
Tsukamoto, H., Komohara, Y., Tomita, Y., Miura, Y., Motoshima, T., Imamura, K., Kimura, T., Ikeda, T., Fujiwara, Y., Yano, H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205378119 · Cited by 86
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
Massari, F., Mollica, V., Rizzo, A., Cosmai, L., Rizzo, M., & Porta, C. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1811226 · Cited by 81
Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis
Chen, C., Guo, Q., Fu, H., Yu, J., Wang, L., Sun, Y., Zhang, J., & Duan, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120988 · Cited by 76
Transient Mild Photothermia Improves Therapeutic Performance of Oral Nanomedicines with Enhanced Accumulation in the Colitis Mucosa
Ma, Y., Gou, S., Zhu, Z., Sun, J., Shahbazi, M., Si, T., Xu, C., Ru, J., Shi, X., Reis, R. L., et al. (2023) · Advanced Materials · doi:10.1002/adma.202309516 · Cited by 72
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors
Pïcca, A., Berzero, G., Bihan, K., Jachiet, V., Januel, É., Coustans, M., Cauquil, C. A., Perrin, J., Berlanga, P., Kramkimel, N., et al. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000967 · Cited by 68
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
Verheijden, R. J., Burgers, F. H., Janssen, J. C., Putker, A. E., Veenstra, S., Hospers, G. A. P., Aarts, M. J. B., Hehenkamp, K. W., Doornebosch, V. L. E., Verhaert, M., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114172 · Cited by 72
Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions
Gang, X., Yan, J., Li, X., Shi, S., Xu, L., Liu, R. M., Cai, L., Li, H., & Zhao, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217241 · Cited by 70
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
Tyan, K., Bagińska, J., Brainard, M., Giobbie‐Hurder, A., Severgnini, M., Manos, M. P., Haq, R., Buchbinder, E. I., Ott, P. A., Hodi, F. S., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02855-1 · Cited by 64
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S. M., Park, E. M., Babcock, R. L., Chrisikos, T. T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221333 · Cited by 63
A Semiconducting Iron‐Chelating Nano‐immunomodulator for Specific and Sensitized Sono‐metallo‐immunotherapy of Cancer
He, S., Yu, J., Xu, M., Zhang, C., Xu, C., Cheng, P., & Pu, K. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202310178 · Cited by 62
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 62
Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy
Dong, X., Pan, P., Ye, J., Zhang, Q., & Zhang, X. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121763 · Cited by 58
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Louedec, F. L., Leenhardt, F., Marin, C., Chatelut, É., Evrard, A., & Ciccolini, J. (2020) · Vaccines · doi:10.3390/vaccines8040632 · Cited by 54
Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?
Katsumoto, T. R., Wilson, K., Giri, V. K., Zhu, H., Anand, S., Ramchandran, K. J., Martin, B. A., Yünce, M., & Muppidi, S. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac012 · Cited by 56
Peripheral nervous system immune-related adverse events due to checkpoint inhibition
O’Hare, M., & Guidon, A. C. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01001-6 · Cited by 56
Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
Apalla, Z., Rapoport, B. L., & Sibaud, V. (2021) · International Journal of Women’s Dermatology · doi:10.1016/j.ijwd.2021.10.005 · Cited by 52
Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver
Shen, S., Dai, H., Fei, Z., Chai, Y., Hao, Y., Fan, Q., Dong, Z., Zhu, Y., Xu, J., Ma, Q., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c02391 · Cited by 52
Autoimmune Myocarditis, Old Dogs and New Tricks.
Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51
Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case–control study
Kowalski, B., Valaperti, A., Bezel, P., Steiner, U. C., Scholtze, D., Wieser, S., Eisenring, M., Widmer, A., Kohler, M., & Franzen, D. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03750-z · Cited by 50
Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang
Ma, J., Yao, Y., Tian, Y., Chen, K., & Liu, B. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00469-5 · Cited by 48
Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 48
Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit
Joseph, A., Simonaggio, A., Stoclin, A., Vieillard‐Baron, A., Géri, G., Oudard, S. M., Michot, J., Lambotte, O., Azoulay, É., & Lemiale, V. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00761-w · Cited by 49
Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
Berg, M. H., Rincon, S. V. D., & Miller, W. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003551 · Cited by 53
Self-citation
Self-delivery of metal-coordinated NIR-II nanoadjuvants for multimodal imaging-guided photothermal-chemodynamic amplified immunotherapy
Dai, Y., Li, X., Xue, Y., Chen, K., Jiao, G., Zhu, L., Li, M., Fan, Q., Dai, Y., Zhao, Q., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.05.032 · Cited by 47
Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy
Gan, M., Liu, N., Li, W., Chen, M., Bai, Z., Liu, D., & Liu, S. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02193-7 · Cited by 50
Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 50
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
Wu, L., Zhang, Z., Bai, M., Yan, Y., Yu, J., & Xu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01139-8 · Cited by 48
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
Lacouture, M. E., Goleva, E., Shah, N. J., Rotemberg, V. M., Kraehenbuehl, L., Ketosugbo, K. F., Merghoub, T., Maier, T., Bang, A., Gu, S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3431 · Cited by 51
Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer
Yu, Y., Wang, S., Su, N., Pan, S., Tu, B., Zhao, J., Shen, Y., Qiu, Q., Liu, X., Luan, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.906824 · Cited by 43
Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Han, X., Wang, M., Zheng, Y., Wang, N., Wu, Y., Ding, C., Jia, X., Yang, R., Geng, M., Chen, Z., et al. (2023) · European Radiology · doi:10.1007/s00330-023-10241-x · Cited by 41
The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
Tang, H. J., Zhou, J., & Bai, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625872 · Cited by 42
Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management
Zhou, Y., Wang, Y., Xia, R.-L., Liu, J., & Ma, X. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.04.19 · Cited by 42
Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Liu, C., Wei, W., Yang, L., Li, J., Cheng, Y., Pu, Y., Yin, T., Na, F., Zhang, L., Fu, P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1173952 · Cited by 43
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Sun, W., Hu, S., & Wang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12587 · Cited by 42
Autoreactive napsin A–specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade
Berner, F., Bomze, D., Lichtensteiger, C., Walter, V. P., Niederer, R., Ali, O. H., Wyss, N., Bauer, J., Freudenmann, L. K., Marcu, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abn9644 · Cited by 40
Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice
Villagrán‐García, M., & Velasco, R. (2022) · Neurological Sciences · doi:10.1007/s10072-022-05920-4 · Cited by 43
Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer
Zubiri, L., Molina, G. E., Mooradian, M. J., Cohen, J. V., Durbin, S., Petrillo, L. A., Boland, G. M., Juric, D., Dougan, M. L., Thomas, M. F., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002886 · Cited by 38
CAR-NK cells in combination therapy against cancer: A potential paradigm
Li, J., Hu, H., Lian, K., Zhang, D., Hu, P., He, Z., Zhang, Z., & Wang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27196 · Cited by 40
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors
Pïcca, A., Valyraki, N. E., Birzu, C., Kramkimel, N., Hermine, O., Zahr, N., Berzero, G., & Psimaras, D. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001073 · Cited by 40
Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors
Vilariño, N., Bruna, J., Kalofonou, F., Anastopoulou, G. G., & Argyriou, A. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165774 · Cited by 37
FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients
Leger, M. C., Routy, B., & Juneau, D. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.04.010 · Cited by 37
Self-citation
Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors
Zhao, L.-J., Li, Y., Jiang, N., Song, X., Xu, J.-H., Zhu, X.-Z., Chen, C., Kong, C., Wang, X.-H., Zong, D., et al. (2022) · Journal of immunotherapy · doi:10.1097/cji.0000000000000415 · Cited by 26
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Choi, J. N., Anderson, R., Blidner, A. G., Cooksley, T., Dougan, M. L., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., Johnson, D. B., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05706-4 · Cited by 35
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35
IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction
Meraviglia-Crivelli, D., Villanueva, H., Zheleva, A., Villalba-Esparza, M., Moreno, B., Menon, A. P., Calvo, A., Cebollero, J., Barainka, M., Mozos, I. R. D. L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01679-6 · Cited by 36
Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review
Filho, P. N., Albuquerque, C., Capella, M. P., & Debiasi, M. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00224-9 · Cited by 39
Progress in nanoparticle-based regulation of immune cells
Fan, Y.-N., Zhao, G., Zhang, Y., Ye, Q., Sun, Y., Shen, S., Liu, Y., Xu, C., & Wang, J. (2023) · Medical Review · doi:10.1515/mr-2022-0047 · Cited by 35
Harnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35
Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors
Mac, Q. D., Sivakumar, A., Phuengkham, H., Xu, C., Bowen, J. R., Su, F., Stentz, S. Z., Sim, H., Harris, A. M., Li, T. T., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00852-y · Cited by 35
Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice
Collier, J. L., Pauken, K. E., Lee, C. A. A., Patterson, D. G., Markson, S. C., Conway, T. S., Fung, M. E., France, J. A., Mucciarone, K., Lian, C. G., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221920 · Cited by 33
Nivolumab-associated DRESS in a genetic susceptible individual
Ai, L., Gao, J., Zhao, S., Li, Q., Cui, Y., Liu, Q., Wu, D., Wang, Y., Jin, X., Ji, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002879 · Cited by 32
Future indications and clinical management for fecal microbiota transplantation (FMT) in immuno-oncology
Jamal, R., Messaoudene, M., de Figuieredo, M., & Routy, B. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101754 · Cited by 31
Self-citation
Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events
Yan, T., Yu, L., Zhang, J., Chen, Y., Fu, Y., Tang, J., & Liao, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1292122 · Cited by 39
Immunoregulatory effects of Huaier (Trametes robiniophila Murr) and relevant clinical applications
Long, H., & Wu, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147098 · Cited by 32
Immune Checkpoint Blockade and Skin Toxicity Pathogenesis
Ma, B., & Anandasabapathy, N. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.06.040 · Cited by 30
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma
Qin, R., Jin, T., & Xu, F. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1326097 · Cited by 30

Authors: Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L.
Affiliations: McGill University (CA)
Cleveland Clinic (US)
Centre Hospitalier de l’Université de Montréal (CA)
Corresponding author: Esfahani, Khashayar
ORCID: Esfahani, Khashayar
Elkrief, Arielle
Calabrese, Cassandra
Lapointe, Réjean
Hudson, Marie
Routy, Bertrand
Miller, Wilson H.
Calabrese, Leonard
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2020-04-03
Volume: 17
Issue: 8
Pages: 504-515
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/s41571-020-0352-8
OpenAlex: W3015154527
Cited by: 351
References: 187
Citations by year: 2026: 39 · 2025: 60 · 2024: 65 · 2023: 56 · 2022: 59 · 2021: 51 · 2020: 20
FWCI: 4.99
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: immune-related adverse events, immune checkpoint inhibitors, personalized treatment, immunohistopathology, immune reconstitution, tumor surveillance, autoimmune disease management, immunopathology
MeSH terms: Antineoplastic Agents, Immunological, Humans, Immunologic Factors, Immunologic Surveillance, Immunotherapy, Neoplasms, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Moving towards personalized treatments of immune-related adverse events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks